

Press release PKvitality
Paris, May 16, 2022



A big push to accelerate diabetes monitoring!

PKvitality Joins Future4care, Europe's Largest eHealth Accelerator



Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe. At the forefront of diabetes innovation, PKvitality has developed K'Watch Glucose, the world's first Continuous Glucose Monitoring (CGM) smartwatch. The acceleration will speed up the development of this unique innovation in diabetes monitoring that takes the form of a smartwatch.

A share ambition: accelerating eHealth

Future4care is Europe's largest open-innovation ecosystem on healthcare created under the initiative of four leading companies: Capgemini, Generali, Orange, and Sanofi. Its ambition is to support emerging companies in bringing their solutions to market and to accelerate future of healthcare for patients, by making the most of the possibilities of digital technology.

PKvitality's mission is to enable everyone to be actively involved in their well-being and health through pleasant and straightforward products. PKvitality is developing K'Watch Glucose, the world's first painless CGM (Continuous Glucose Monitor) smartwatch that will track glucose levels continuously and discreetly. The system will measure glucose levels by analyzing interstitial fluid (ISF) thanks to Skintaste, a patented system using micropoints. The system enables a painless and non-stigmatizing experience in a design-to-cost architecture. Using the same technology, they are developing K'Watch

Athlete, a real-time lactate monitoring design that will allow athletes and trainers to significantly improve training and performance while reducing the risk of injuries.

PKvitality has the support of Bpifrance and EIC accelerator, is accelerated by Dassault Systemes and is the winner of multiple awards, including Best of CES, EIT Health Catapult, and the Healthcare Innovation World Cup.

Minh Lê, General Manager of PKvitality, declared: *“The support from Future4care and its four leading founders will significantly help us to move from Research & Development activities to industrialization and commercialization of our solutions. We have grown up from 10 to 40 people in the last two years, and we plan to be more than one hundred by 2023. Future4care will be a major support in that scaleup phase, from regulatory and market access to business development and AI, from consolidating existing teams to creating new functions as sales is approaching.”*

Agnès De Leersnyder, CEO of Future4care, declared: *“We are delighted to be welcoming PKvitality to join the Future4care accelerator, among twenty-one other health startups. They have shown promising results as a growing scaleup in the bio wearables sector. PKvitality is exactly the type of scaleup that aligns with the vision of Future4care. As they are developing the first ever CGM smartwatch, we are determined to support them by welcoming them into the our community and offering the best office spaces, networking, and acceleration program.”*

The Future4care accelerator came at the perfect time for PKvitality which is progressing very fast: beginning of their first clinical trials in November 2021, closing of its €6m Series A in January 2022, they are also present on [the crowdfunding platform Wiseed](#) which is open to any investor.

K'Watch Glucose, the 1st smartwatch to monitor glucose

K'Watch will be the first Continuous Glucose Monitor in the form of a smartwatch. It is composed of two parts: K'Watch, the smartwatch and K'apsul, an adhesive patch at the back. It will enable a continuous monitoring of systemic glucose levels anytime and anywhere. This is possible thanks to SkinTaste®, a patented biosensor array that uses micropoints (<1mm long) in order to analyze chemical compositions of the interstitial fluid. Completely painless and invisible to others, the diabetes patient will be able to check its level discreetly or follow its average glucose and time in range.



To access the PKvitality crowdfunding on Wiseed: [la plateforme de crowdfunding Wiseed](#)

To access visuals, please click [here](#)

About Future4care

Future4care is a European e-health startup accelerator launched in January 2021, co-founded by four major European companies - Capgemini, Generali, Orange and Sanofi - with the common ambition of supporting startups in their transition to scale, in order to strengthen European health sovereignty and decompartmentalize interactions between healthcare system players. Future4care's mission is to

accelerate the development of e-health solutions until they reach the market. Focused on startups that want to accelerate their scaling up to industrialization, Future4care's service offer allows them to host their company in the Biopark building (6,400 m²) in the 13th arrondissement of Paris, and to benefit from customized support combining access to knowledge and connections with experts from our network. Future4care is also a forward-looking digital health center. Its reflections and actions will concern subjects related to usage, ethics, and French and European economic sovereignty. The Future4care Institute will be distinguished by its highly expert positioning, its objectivity, and its commitment to progress in digital health. It will be guided by an interdisciplinary, scientific and ethical committee.

More information on: <https://future4care.com/fr>

About PKvitality

PKvitality is a health & sport bio-wearable scale-up currently working on K'Watch Glucose, a Continuous Glucose Monitoring (CGM) device in the form of a smartwatch presently in clinical trials. It will enable a painless, discreet and precise monitoring of systemic glucose level anytime and anywhere. Using the same technology, PKvitality is also working on K'Watch Athlete, a smartwatch which will provide real-time monitoring of their lactic acid – an indicator of muscle fatigue – to significantly improve an athlete's training and performance.

More information on: www.pkvitality.com

Press Contacts

Jean-François Kitten - jf@licencek.com - +33(0)6 11 29 30 28

Ilinca Spita – i.spita@licencek.com - +33(0)6 64 75 12 98 (EN)

Constance Leglise – c.leglise@licencek.com +33(0)6 65 20 00 56

Investor Contact

Contact-funding@pkvitality.com



This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 960071.